Skip to content
To the full analysis

City Therapeutics Stock: Key Metrics

CTY
$18.35Closing price of 19 Nov 2026MEQIRI Score 58 out of 100

City Therapeutics had an operating margin of 35.4% and a return on invested capital (ROIC) of 13.4% in fiscal 2019.

Margins show how much of revenue is left over, returns on capital how hard the invested money works.

Daily figure as of 20 Nov 2026

Margins

  • Gross margin
  • Operating margin
  • Net margin
Figures as a table
YearGross marginOperating marginNet margin
200576.3%9.8%9.7%
200676.5%12.2%12.2%
200778.4%24.1%15.1%
200883.8%21.8%13.8%
200984.5%26.3%12.3%
201082.1%26.8%11.7%
201172.4%18.1%8.2%
201267.6%21.5%9.6%
201368.1%23.7%11.0%
201467.4%23.9%11.0%
201568.0%25.2%12.0%
201667.1%26.1%12.2%
201766.3%27.1%19.4%
201867.4%31.3%19.6%
201970.1%35.4%22.4%

Returns on Capital

  • ROE
  • ROIC
  • ROA
Figures as a table
YearROEROICROA
200541.8%no data−100.0%
200669.5%8.2%8.1%
2007152.7%17.0%200.0%
2008183.0%17.0%200.0%
2009200.0%19.2%102.7%
2010−100.0%19.6%200.0%
20115.5%5.9%3.1%
20128.5%6.5%5.1%
201310.0%7.4%6.0%
201410.6%7.6%4.3%
201512.1%8.6%5.0%
201612.5%8.9%5.1%
201717.7%13.1%7.9%
201816.9%12.6%8.1%
201918.1%13.4%8.7%
Buyback calculator for City Therapeutics

Data and Required Disclosures

  • ; time horizon around 12 months
  • Rated Neutral since 7 Nov 2026
  • Price: closing price of 19 Nov 2026
  • Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2019. MEQIRI calculates the score and fair value itself every night.
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.